4:52 PM
Jul 11, 2013
 |  BC Extra  |  Clinical News

ALK-Abello's dust mite immunotherapy meets in second Phase III

ALK-Abello A/S (CSE:ALK-B) said once-daily HDM AIT for up to 18 months met the primary endpoint of reducing the risk of moderate to severe asthma exacerbations vs. placebo in the Phase III MITRA (MT-04) trial to treat house dust mite-induced...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >